The read at a glance
Computed from the FY2026 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 7.31 — safe zoneOK
- Earnings-manipulation signal · Beneish M -3.09 — no flag raisedOK
- Earnings quality 59/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2026, as China SXT Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Revenues generated from third parties$1.1M
- Regular TCMP$1.1M
- Advanced TCMP$50K
- Others$7K
- Revenue generated from related parties$41
Latest filings
- 6-K · Company announcement (foreign filer)2026-08-28
- 6-K · Company announcement (foreign filer)2026-07-24
- 6-K · Company announcement (foreign filer)2026-07-06
- 20-F · Annual report (foreign filer)2026-07-01
- 6-K · Company announcement (foreign filer)2026-06-01
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about China SXT Pharmaceuticals, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when China SXT Pharmaceuticals, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.